Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rSh28GST
- Development stage
- Phase 3
- Lead developer
- Atos
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
rSh28GST is a recombinant protein vaccine candidate composed of the 28-kDa glutathione S-transferase (GST) enzyme from *Schistosoma haematobium*, produced in *Saccharomyces cerevisiae*. It is designed as a therapeutic and prophylactic vaccine for urinary schistosomiasis. The mechanism involves inducing a Th2-type immune response with antibodies that inhibit the enzymatic activity of the parasite's GST, potentially reducing worm fecundity and egg viability. Clinical trials have shown it to be immunogenic and well-tolerated but efficacy endpoints in phase 3 trials were not met. The product is also known as Bilhvax when formulated with Alhydrogel (aluminum hydroxide) adjuvant[1][2][5][7][8].
- Brand names
- Bilhvax
- Other names
- recombinant 28-kDa glutathione S-transferase of Schistosoma haematobiumrecombinant28-kDa glutathione S-transferase of Schistosoma haematobiumrecombinant-28-kDa glutathione S-transferase of Schistosoma haematobium28 kDa GST of Schistosoma haematobium
02
Targets
GSTP1 (Glutathione S-transferase P)GST (Glutathione S-transferase alpha 3)
Beyond the preview
Go deeper on rSh28GST.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rSh28GST.